Developing treatments for millions of patients with anxiety and stress disorders
Bionomics is a global, clinical-stage biotechnology company focused on developing novel, first-in-class, ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders.
Utilizing our deep expertise in ion channel biology and translational medicine, we design best-in-class oral, small molecules to modulate ion channel function, influence neurotransmission and consequently downstream signaling in the brain.
We are currently focused on our proprietary Negative Allosteric Modulators (“NAMs”) of the α7 receptor developed for the treatment of anxiety and stressor related disorders.
Bionomics’ lead asset BNC210 is a small molecule with unique properties and a highly differentiated emerging profile with non-sedating, non-habit forming, non-cognition impairing anxiolytic and antidepressant properties.
BNC210 is currently in late-stage development for the treatment of Social Anxiety Disorder (Phase 3) and Post-Traumatic Stress Disorder (Ph3 start-up phase).
